173944-98-4

Basic information

• Product Name: Benzoic acid, 3-[[(4-nitrophenoxy)carbonyl]amino]-, 1,1-dimethylethyl ester
• CAS NO: 173944-98-4
• Molecular Formula: C18H18N2O6
• Molecular Weight: 358.351
• Mol File: 173944-98-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-[[(4-nitrophenoxy)carbonyl]amino]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-[[(4-nitrophenoxy)carbonyl]amino]-, 1,1-dimethylethyl ester(173944-98-4)
• EPA Substance Registry System: Benzoic acid, 3-[[(4-nitrophenoxy)carbonyl]amino]-, 1,1-dimethylethyl ester(173944-98-4)

Safety Data

• Hazardous Substances Data: 173944-98-4(Hazardous Substances Data)

Upstream product

• 92146-82-2 tert-butyl 3-aminobenzoate 
• 7693-46-1 4-Nitrophenyl chloroformate 

Downstream Products

• 173459-74-0 3-[3-(1-{[isopropyl-(4-methoxy-phenyl)-carbamoyl]-methyl}-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)-ureido]-benzoic acid tert-butyl ester 

Relevant articles and documents

METHOD OF INDUCING CHOLECYSTOKININ AGONIST ACTIVITY USING 1,4-BENZODIAZEPINE COMPOUNDS

A method of inducing a Cholescystokinin-A receptor agonist response in a mammal by administering a compound of formula (I), STR1 where R 1 is C 1-C 6 alkyl, C 3-6 cycloalkyl, phenyl, or substituted phenyl; R 2 is C 3-6 alkyl, C 3-6 cycloalkyl, C 3-6 alkenyl, benzyl, phenylC 1-3 alkyl or substituted phenyl; or NR 1 R 2 together form 1,2,3,4-tetrahydroquinoline or benzazepine mono-, di-, or trisubstituted independently with C 1-6 alkyl, C 1-6 alkoxy or halogen substituents; n is an integer selected from the grouping consisting of 0, 1,2 or 3; p is the integer 0 or 1; q is the integer 0 or 1; r is the integer 0 or 1, provided that when q is 0 then r is 0; R 3, R 4, R 5 and R 8 are selected from a variety of substituents; X is nitrogen, nitroso or R 8 ; m is an integer selected from the group consisting of 0, 1, 2 or 3; Y and Z are hydrogen or halogen, novel intermediates, a pharmaceutical composition for treating obesity, gall bladder stasis, disorders of pancreatic secretion, methods for such treatment and processes for preparing compounds of formula (I).